Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DM9GO4
|
|||
| Drug Name |
IO-202
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1 | [1] | |
| Chronic myelomonocytic leukaemia [ICD-11: 2A40; ICD-10: C93.1] | Phase 1 | [1] | ||
| Company |
Immune-Onc Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte immunoglobulin-like receptor B4 (LILRB4) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04372433) IO-202 as Monotherapy in Patients in AML and CMML. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Immune-Onc Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.